EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms

Gina M Morgan iD, John H Kimbrough iD, Maura H Karr, Jennifer Thompson, Josh West, Mariana Castanheira, S J Ryan Arends iD, Nicole Scangarella-Oman iD

Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)

DOI: 10.1128/aac.01832-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Gina M Morgan und 7 weiteren Autor:innen. Beteiligte Einrichtung: JMI Laboratories/Element Materials Technology, North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Acenaphthenes, Anti-Bacterial Agents, Levofloxacin, Gram-Negative Bacteria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antimicrobial recently approved by the Food and Drug Administration (FDA) and Medicines and Healthcare products Regulatory Agency for the treatment of uncomplicated urinary tract infections (uUTI) and by the FDA for uncomplicated urogenital gonorrhea. Gepotidacin selectively inhibits type II topoisomerases involved in bacterial DNA replication by a distinct binding site and novel mechanism of action, conferring in vitro activity against most uropathogens, including those resistant to current antimicrobials. This study evaluated the potential of gepotidacin to select for spontaneous resistance in Citrobacter freundii , Enterobacter cloacae species complex, Klebsiella aerogenes , Klebsiella pneumoniae , Proteus mirabilis , Providencia rettgeri , Enterococcus faecalis , and Staphylococcus saprophyticus clinical isolates. Mutant frequencies ranged from 6.1 × 10 −8 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcenaphthenesAnti-Bacterial AgentsLevofloxacinGram-Negative BacteriaHeterocyclic Compounds, 3-RingGram-Positive BacteriaDrug Resistance, BacterialMicrobial Sensitivity TestsMutationEnterococcus faecalis

Stichwörter der Autor:innen

SNPfrequency of resistancegepotidacingepotidacin target-based mutationsresistance mechanisms

Substanzen

gepotidacinAcenaphthenesAnti-Bacterial AgentsLevofloxacinHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • JMI Laboratories/Element Materials Technology, North Liberty, Iowa, USA.
  • GSK, Collegeville, Pennsylvania, USA.

ORCID-Profile: Gina M Morgan, John H Kimbrough, S J Ryan Arends, Nicole Scangarella-Oman

Förderung

  • GlaxoSmithKline

Zitieren

APA

Morgan, G. M., Kimbrough, J. H., Karr, M. H., Thompson, J., West, J., Castanheira, M., Arends, S. J. R., & Scangarella-Oman, N. (2026). Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01832-25

Vancouver

Morgan GM, Kimbrough JH, Karr MH, Thompson J, West J, Castanheira M, et al. Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01832-25

BibTeX
@article{Morgan2026,
  author = {Morgan, Gina M and Kimbrough, John H and Karr, Maura H and Thompson, Jennifer and West, Josh and Castanheira, Mariana and Arends, S J Ryan and Scangarella-Oman, Nicole},
  title = {Determination of frequency of spontaneous resistance for gepotidacin and levofloxacin against a collection of gram-positive and gram-negative organisms},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {6},
  doi = {10.1128/aac.01832-25}
}
Kostenlos starten →